54b4213be8
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
46 lines
No EOL
2.3 KiB
Markdown
46 lines
No EOL
2.3 KiB
Markdown
# LIXIPARK Trial
|
|
|
|
**Type:** Phase 2 randomized controlled trial
|
|
**Indication:** Early Parkinson's disease
|
|
**Drug:** Lixisenatide (GLP-1 receptor agonist)
|
|
**Status:** Completed, published NEJM April 2024
|
|
**Primary endpoint:** MDS-UPDRS Part III motor score at 12 months — MET
|
|
|
|
## Design
|
|
- **N:** 156 patients (75 lixisenatide, 75 placebo; some sources report 150)
|
|
- **Population:** Early Parkinson's disease (<3 years since diagnosis)
|
|
- **Duration:** 12 months
|
|
- **Design:** Double-blind, placebo-controlled
|
|
- **Administration:** Daily subcutaneous injection
|
|
|
|
## Results
|
|
**Primary endpoint (12 months):**
|
|
- Placebo group: MDS-UPDRS Part III worsened by +3.04 points (disease progression)
|
|
- Lixisenatide group: Remained at baseline (0 change)
|
|
- Between-group difference: Statistically significant
|
|
- Interpretation: Lixisenatide halted motor symptom progression over 12 months
|
|
|
|
**Safety:**
|
|
- >50% of lixisenatide patients reported significant GI side effects (nausea, vomiting)
|
|
- >1/3 required dose reduction due to GI tolerability
|
|
- Safety profile is a major practical concern for real-world implementation
|
|
|
|
## Limitations
|
|
- Phase 2 (not Phase 3 — not definitive)
|
|
- 12 months (shorter than exenatide Phase 3 at 96 weeks)
|
|
- No DaT-SPECT brain imaging to confirm neuroprotection vs. symptomatic benefit
|
|
- Off-label use NOT recommended pending Phase 3 confirmation
|
|
|
|
## Context
|
|
- Preliminary results presented at 2023 International Parkinson and Movement Disorder Society congress (Copenhagen)
|
|
- Published NEJM April 2024
|
|
- As of May 2026, no Phase 3 funding announced despite positive Phase 2 result
|
|
- Contrasts with exenatide Phase 3 failure (Lancet February 2025)
|
|
|
|
## Mechanistic hypothesis
|
|
Lixisenatide crosses BBB via adsorption transcytosis (Holscher 2024). Holscher identifies lixisenatide as having "strongest neuroprotective effect" among GLP-1 agonists in clinical trials, correlating with BBB penetrance mechanism. The divergence from exenatide suggests regional CNS penetrance (specifically substantia nigra) may determine efficacy.
|
|
|
|
## Timeline
|
|
- **2023** — Preliminary results presented at International Parkinson and Movement Disorder Society congress, Copenhagen
|
|
- **2024-04-04** — Full results published in New England Journal of Medicine
|
|
- **2026-05** — No Phase 3 funding announced; exenatide Phase 3 failure may have chilled further GLP-1 Parkinson's investment |